Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
238.15(c) 220.45(c) 241.49(c) 239.82(c) 238.55(c) Last
4 361 666 4 125 123 3 627 336 2 853 320 1 121 303 Volume
+2.08% -7.43% +9.54% -0.69% -0.53% Change
More quotes
Financials
Sales 2021 12 357 M 14 950 M 14 950 M
Net income 2021 6 910 M 8 360 M 8 360 M
Net cash position 2021 7 694 M 9 307 M 9 307 M
P/E ratio 2021 6,83x
Yield 2021 -
Sales 2022 10 347 M 12 518 M 12 518 M
Net income 2022 6 625 M 8 015 M 8 015 M
Net cash position 2022 12 670 M 15 328 M 15 328 M
P/E ratio 2022 7,85x
Yield 2022 -
Capitalization 47 584 M 57 615 M 57 566 M
EV / Sales 2021 3,23x
EV / Sales 2022 3,37x
Nbr of Employees 2 200
Free-Float 87,3%
More Financials
Company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer... 
More about the company
Ratings of BioNTech SE
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BIONTECH SE
06/13ASTRAZENECAá : Germany demands that J&J make up COVID-19 vaccine gap in July
RE
06/11FDA Approves Export of Covid-19 Vaccine Doses From Troubled Baltimore Plan --..
DJ
06/11FDA Approves Export of Covid-19 Vaccine Doses from Troubled Baltimore Plant
DJ
06/11Brazil Approves Pfizer/BioNTech COVID-19 Vaccine For Children 12-15 Years Old
MT
06/11Can Schools Mandate Covid-19 Vaccines for Children? What We Know
DJ
06/11BIONTECHá : Pfizer To Supply Limited COVID-19 Vaccines To Scotland, England For ..
MT
06/11Drug Experts Explore Mixing COVID-19 Jabs Despite Side Effect Risks
MT
06/11"WE NEED MORE" : UN joins criticism of G7 vaccine pledge
RE
06/11MARKET CHATTER : China Merchants Group Leads $200 Million Funding Round For Vacc..
MT
06/10U.S. Covid-19 Vaccine Donation to Boost Developing World's Pandemic Fight -- ..
DJ
06/10Moderna Submits FDA Emergency Use Authorization for COVID-19 Vaccine in Adole..
MT
06/10European Shares End Mixed As US Inflation Jumps
MT
06/10Moderna's Covid-19 Vaccine Seeks FDA Authorization for Use in Adolescents
DJ
06/10MARKET CHATTER : COVID-19 Vaccine Producers To Gain Legal Indemnity In India
MT
06/10ETF PREVIEW : ETFs, Futures Mostly Mixed Premarket as Wall Street Awaits Inflati..
MT
More news
News in other languages on BIONTECH SE
06/13GESAMT-G7 einigt sich auf Impfversprechen und harten China-Kurs
06/13Ministerium erwartet von Johnson & Johnson Nachlieferungen im Juli
06/13MERKEL : 'Erheblicher Beitrag' zur Impfstoffverteilung aus Deutschland
06/12G7 kontert Chinas 'Neue Seidenstraße' mit Milliarden-Initiative
06/12Zweiter Impfstoff für Betriebsärzte - Laschet greift SPD an
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 145,96 €
Last Close Price 197,02 €
Spread / Highest target 0,86%
Spread / Average Target -25,9%
Spread / Lowest Target -53,6%
EPS Revisions
Managers and Directors
NameTitle
Ugur Sahin Chief Executive Officer
Sierk P÷tting Chief Operating & Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Christoph Huber Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BIONTECH SE192.63%57 615
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
REGENERON PHARMACEUTICALS8.78%54 424
VERTEX PHARMACEUTICALS-18.33%49 966
BEIGENE, LTD.34.26%31 922